Research programme: heart muscle regeneration peptides - StemPath
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator StemPath
- Mechanism of Action Stem cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in Canada
- 15 Mar 2007 FLS removed - company website undergoing revamp.
- 03 Mar 2006 Preclinical trials in Myocardial infarction in Canada (unspecified route)